Introduction
The relationship of blood pressure (BP) to the risk of cardiovascular disorders has been well known for a long time, from the data of established epidemiological studies. 1, 2 However, the cardiovascular complications of hypertension are considerably reduced after anti-hypertensive therapy. That was initially apparent during treatment of malignant hypertension, when therapy improved a 5-year survival rate up to 30%. 3 It was later verified that the treatment of moderate or severe hypertension led to the reduction of cardiovascular disorders. 4 Subsequent studies, whether multicentred or not, confirmed the benefits of hypertension therapy, whereas due to the high number of participant patients they managed to show improvement even on the therapy of mild hypertension. 5 Moreover, anti-hypertensive treatment appeared to significantly reduce cardiovascular mortality and morbidity in patients over 60 years of age. 6 However, after the follow-up of 3783 Scottish patients in a hypertension clinic for 6.5 years, 7 as well as 686 Swedish middle-aged men for 10 years, 8 Correspondence: Dr Athanasios G Trikas, 52 Bizaniou Street, Panorama Voulas, 16673 Athens, Greece Received 20 July 1997; revised 25 October 1997; accepted 9 January 1998 degree (−0.4 and −0.8%, P Ͻ Ͻ Ͻ 0.0001), with the greatest decrease in patients with lower DBP levels under treatment (P Ͻ Ͻ Ͻ 0.0001). LV systolic function improved to a modest degree (0.8%, P Ͻ Ͻ Ͻ 0.0001), depending on DBP fall (P Ͻ Ͻ Ͻ 0.0001), as did cardiac output (2.4%, P Ͻ Ͻ Ͻ 0.0001). LV systolic wall stress and total peripheral resistance fell (−18% and −14%, P Ͻ Ͻ Ͻ 0.0001) in relation to DBP drop (P Ͻ Ͻ Ͻ 0.0001), as did aortic root distensibility (55%, P Ͻ 0.0001). It is concluded that the degree of cardiovascular structure and function improvements are directly related to the DBP levels achieved under felodipine anti-hypertensive therapy.
it was established that although the cardiovascular complications were reduced by hypertension therapy, the stroke episodes and the myocardial infarctions remained at higher levels in the hypertensive patients under treatment compared to the normotensive population sample of similar age.
This failure in normalising cardiovascular risk is possibly due to many factors. Firstly, long-term survival depends on the parallel treatment of other risk factors, where the various anti-hypertensive drugs, in spite of BP reduction, may possibly cause certain metabolic parameters to deteriorate. 9 Secondly, the structural changes of the cardiovascular system due to chronic hypertension are not always reversible with anti-hypertensive therapy, while they depend on the severity of the disease, as well as the type of pharmaceutical treatment applied. 10 Thirdly, as shown by extensive studies, the BP of hypertensive patients is not always satisfactorily reduced by treatment and it never reaches the BP levels of normotensive individuals in the same age group. It is well known that cardiovascular disorders are better related to the levels of BP under treatment, rather than its severity before the initiation of treatment, whereas in extensive studies it was established that the patients who most benefited were those with the lowest BP under treatment. 5, 7 It is the aim of the HOT study to answer this question in which using felodipine as the basic thera-peutic drug, the survival of patients in relation to the levels of diastolic BP (DBP) maintained under treatment will be analysed, not only on levels lower than 90 mm Hg, but also under 80 mm Hg.
The purpose of the present study is to verify the degree of improvement of cardiovascular structure and function after a 6-month anti-hypertensive monotherapy with felodipine, in proportion to the levels of DBP obtained under treatment, according to the standards of the HOT study.
Materials and methods
One thousand patients of both sexes, with essential hypertension, stage I and II, were initially included in the study. 11 After a 2-week washout period, a placebo was issued for 2 weeks followed by a full clinical and laboratory control, where patients with secondary hypertension were excluded.
Patients with acute or chronic inflammatory or systemic disease, endocrine disorder, renal or cardiac failure, coronary artery disease, chronic pulmonary disease, history of cerebrovascular accident or lack of tolerance to dihydropyridines, major arrhythmias or conduction defects, severe sinus bradycardia (Ͻ55 beats/min) or tachycardia (Ͼ100 beats/min), morbid obesity (body mass index (BMI) Ͼ36 kg/m 2 ), poor echocardiographic imaging or poor patient compliance were not included in the study.
Each patient received 5 mg of felodipine once daily. If the patients BP was not normalised within the first month of therapy, felodipine was increased to 10 mg once daily (38% of patients). On every visit to the out-patient clinic (weeks −4, −2, 0, 1, 2, 4, 6, 8, 12, 16, 20, 24) , the systolic and diastolic (stage V) BP (SBP and DBP) and heart rate at rest (HR) in the sitting and standing positions were measured three times at 1 min intervals with a mercury sphygmomanometer, and their mean value was used. Target BP was reached when DBP Ͻ95 mm Hg with simultaneous reduction of DBP Ͼ10 mm Hg, in comparison to the last day of treatment with placebo (week 0) in the sitting position. Of the 1000 patients, 622 normalised BP within a month of treatment initiation, without any serious side effects. The final cohort included 600 patients, while 22 patients were excluded, either because the addition of another anti-hypertensive drug was required, unrelated illness, or due to patient bad compliance.
At the end of the study (week 24), the clinical and laboratory control was repeated and subsequently the patients were divided into four groups, according to their DBP levels under treatment (Table 1) : there were 86 patients with a DBP of 90-94 mm Hg, . Echocardiographic studies were performed with an ATL Ultramark 8 machine, on weeks 0 and 24, blind to BP levels, by the same cardiologist. The methodology that was followed on the measurements of echocardiographic dimensions of the left ventricle (LV) and the calculation of its structural and functional indices, have been previously reported. [12] [13] [14] From the two-dimensional echocardiogram, M-mode measurements of LV at the level of tenondae chordae were obtained [end-diastolic (EDD) and end-systolic (ESD) diameters] and the thickness of intraventricular (IVS) and posterior wall (PW) of the LV were measured at the same time according to the American Society of Echocardiography criteria. From these measurements, the following parameters were calculated: the cross-sectional
.6], the LV mass index dividing by body surface area (LVMI = LVM/BSA), the ratio of LV mass to volume (M/V), the relative wall thickness (RWT = IVS + PW/EDD). The LV volumes (EDV and ESV) were measured using the Teicholz method as well as their indices (EDVI and ESVI) after division with BSA. The stroke volume index (SVI = EDVI − ESVI), the cardiac index (CI = HR×SVI), the fractional shortening (FS = EDD − ESD/EDD), the ejection fraction (EF = EDV − ESV/EDV), the mean rate of circumferential fibre shortening (Vcf = EDD − ESD/EDD × ET, where ET = ejection time of LV), the LV systolic wall stress [ = 0.344 (SBP × ESD)/h(1 + h/EDD), where h is related to systolic data, and the total peripheral resistances (TPR) were calculated as well.
Aortic root end-systolic (AoS) and end-diastolic (AoD) diameters were each calculated from three measurements, and the mean value was used: from the M-mode tracing, 3 cm above the aortic valve; from direct measurement of the two-dimensional frames; and from indirect calculation, using the twodimensional image diameters, perimeters and areas, at end-systole and end-diastole. The percentage change of the aortic root was calculated, % ⌬A o = 100 (AoS − AoD)/CAoS), to obtain the aortic strain. Pulse pressure (PP) was obtained from the systolic minus the diastolic BP, and the following indices of the elastic properties of the aorta were calculated: For the transformation of the pressure units from mm Hg to dynes/cm 2 , the factor 333 was used. The mean value and the standard deviation in all the parameters was calculated before and after treatment. In addition their percentage change (%⌬) in total and separately in the four groups was measured according to the DBP values. For the evaluation of the rate of change of the echocardiographic indices the Student's paired t-test was used, while for the comparison of the changes among the four groups, the criteria F-Fisher was evaluated after ANOVA analysis. For the evaluation of the simultaneous change of the LV mass and function and the aortic root in relation to the age, obesity and BP reduction, the values of the Pearson's coefficient of correlation were used. To compare slopes, the Z criterion was applied. A P-value Ͻ0.05 was considered significant. Table 2 shows the results of this study, in the total number of patients as well as in the four groups according to the values of the DBP under treatment.
Results
BP was reduced significantly (from 175/103 to 137/83 mm Hg) in the 600 patients, who normalised their BP 1 month after treatment initiation. Of course, the decrease of both SBP and DBP differed among the four subgroups (P Ͻ 0.0001) by definition. Heart rate showed a small but significant increase (from 71 to 73 bpm, P Ͻ 0.0001).
There was a small reduction of LV dimensions in all patients which was more apparent at end-systole (−0.8%, P Ͻ 0.0001). However, patients under treatment with the highest DBP values developed a small but significant increase of LV dimensions (0.9 and 1.6%, P Ͻ 0.001), while a higher reduction of LV dimensions was observed in patients with the highest DBP reduction (−1.2% and −2.2%, P Ͻ 0.001). The LV wall thickness was significantly reduced, in particular in the intraventricular septum (−9.6% and −5.7%, P Ͻ 0.0001), and were influenced by the degree of the DBP reduction (P = 0.001 for IVS and P Ͻ 0.0001 for PW reduction, respectively).
So, the lower the values of DBP under treatment the higher the reduction of LV hypertrophy indices; the LV mass index was reduced from 148 to 130 g/m 2 (P Ͻ 0.0001), in relation to the DBP (−8.2, −11.1, −12.9, −14.4%, P Ͻ 0.0001). This myocardial mass reduction was mainly due to the wall thickness changes than to the LV cavity, as it is also apparent from the reduction of the assymetry indices (M/V and RWT, P Ͻ 0.0001). The RWT, however, was dependent on the DBP under treatment to only a small degree (P = 0.03).
The LV systolic function indices were improved to a small but significant degree in all patients (from 0.8% to 4.0%, P Ͻ 0.0001) and especially in those with the lowest values of DBP (P Ͻ 0.0001). It is worth noting that the systolic indices like fractional shortening (FS) and ejection fraction (EF) deteriorated in the patient group with DBP 94 -90 mm Hg, while they significantly improved (P Ͻ 0.0001) in the other three DBP groups, although the magnitude of these changes is of little clinical importance. Cardiac output was increased (2.4%, P Ͻ 0.0001), with a parallel drop in total reduction of peripheral resistances (−14.2%, P Ͻ 0.0001) especially in patients with the lowest DBP (−17.2%, P Ͻ 0.0001). Besides, all the aortic root functional indices were improved particularly in relation to the degree of the DBP reduction (P Ͻ 0.0001). Table 3 shows the relations of the degree of changes in echocardiographic indices before and after treatment to the degree of BP (SBP and DBP) changes, age and obesity of patients. The degree of SBP reduction was profoundly related (P Ͻ 0.0001) to the level of LV systolic stress reduction (r = 0.79) and the degree of aortic root functional improvement (r = 0.78), while the DBP reduction magnitude was better related to the reduction of LV hypertrophy (r = 0.32). Cardiac output was independent of BP reduction (P = NS), while peripheral resistances were reduced in parallel to the reduction of both the SBP and DBP (r = −0.53 and r = −0.52, P Ͻ 0.0001). Patient age influenced LV mass reduction to a small degree only (r = −0.21), but not its functional improvement, cardiac output and peripheral resistances. In contrast, it affected more the improvement of the aortic root functional properties (r = −0.37). Finally, obesity played a smaller role mostly affecting the degree of LV mass reduction (r = −0.18).
Discussion
Felodipine is a second generation dihydropyridine, which inhibits the slow entry current of calcium ions in the reticulum, while its intracellular accumulation inhibits calcium release from the intracellular reserves. 15 The vascular selectivity of felodipine is particularly strong, 16 with a ratio 100:1 to the myocardium, with the exclusive target being the relaxation of the resistance vessels, without any effect on the venous circulation, as has been shown in normal controls, 17 in patients with coronary artery disease 18 and in hypertensive patients.
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The anti-hypertensive effect of felodipine is well established [20] [21] [22] and it appears that its efficacy is dose-dependent with a wide therapeutic range from 2.5 to 20 mg daily, even though the usual clinical practice reports BP treatment using 5-10 mg daily. 22 The percentage of patients with BP normalisation (DBP р90 mm Hg) is reported from relatively low (46%) up to ideal (100%), while the BP reduction in extensive multicentre studies is particularly satisfactory (from 172/103 to 146/86 mm Hg) in 652 patients, in short-term (4-week) as well as long-term (1 year) studies. 23 The material of the present study is referred only to patients who normalised their BP with felodipine monotherapy. Mean BP reduction was 36/19 mm Hg, while 20% of the study patients reduced DBP under 80 mm Hg. The superiority of anti-hypertensive action of felodipine in comparison to diuretics, such as hydrochlorothiazide and chlorothalidone, to ACE-inhibitors, like captopril and enalapril, 24 and even to calcium antagonists such as dihydropyridines nitrendipine and nifedipine, 25 has been reported in many studies. The anti-hypertensive therapy with vasodilator drugs can produce reflex tachycardia, due to peripheral blood pooling and reduction of venous return. An acute administration of felodipine may result in considerable tachycardia, which is however, minimised or abolished by chronic therapy. In this study we observed an increase in the mean heart rate by only 3 beats/min, which was significant (5%) in the patient group who reduced DBP Ͻ80 mm Hg. It should be mentioned that none of the 600 patients of this study had episodes of paroxysmal or clinically important (Ͼ100 beats/min) tachycardia during the 6-month treatment period with felodipine.
In chronic hypertension the increase in LV systolic stress causes chamber wall hypertrophy, with no increase in LV dimension, as a normal compensative mechanism. 26 Thus, the hypertrophic myocardium achieves distribution of pressure load on a wider transmural surface, maintaining LV stress, muscular shortening and pulse volume within normal range. 27 However, despite the benefits of adaptation, LV hypertrophy increases cardiovascular risk, independently of the high BP levels. 28 Although the mechanisms responsible for the increased danger are not completely defined, they include the modified response to adrenergic stimulation, sodium and calcium intracellular metabolism changes, coronary flow and reserve reduction, increased arrhythmiogenesis and decrease of the ventricular fibrillation threshold, development of congestive heart failure in parallel to the progressive degeneration of myocytes and their replacement by connective tissue. 29 So, a basic target of anti-hypertensive therapy is the regression of LV hypertrophy. This is achieved by the use of different anti-hypertensive drugs and, at least on a short-term basis, it seems to be independent of BP levels and the degree of cardiac wall hypertrophy. 30 The calcium antagonists have been shown to achieve regression of LV hypertrophy after 6 months of therapy. 30 Felodipine reduces canine cardiac mass 31 as well as in the hypertensive patient. 32 So, the reduction of LV mass index after felodipine treatment for 6 to 12 months is reported to reach up to 20% or even 25%. In the present 600-patient study we noted a reduction of the LV mass index by 12% after a 6-month felodipine monotherapy. The myocardial mass reduction resulted from the ventricular wall thickness reduction, in particular of the intraventricular septum (−10%), as it was also established in a 76-patient study (−15%). The interesting finding of the present study is that the degree of cardiac hypertrophy regression was parallel to the BP reduction levels (−9, −12, −13, −15%). It appears that the degree of improvement in LV structural characteristics reflects the individual answer of hypertensive patients to BP reduction with the same drug, during the same length of therapy. The vasodilative properties of dihydropyridines favour the haemodynamic balance through the afterload reduction. However, first generation calcium antagonists neutralised this advantage by the unstable answer of the patients, while a negative inotropic action of nifedipine was also established especially in patients with severe heart failure. Second generation agents tried to overcome this disadvantage with various degrees of success. Indeed, it has been shown in experimental studies, that felodipine has a positive inotropic action. This does not appear to be a class effect, since an increase with felodipine and a decrease with amlodipine in LV contractility were observed. 33 But it also appears that felodipine has some beneficial effects in the myocardial contractility in patients with or without heart failure. 34 In the present study we observed that all LV systolic indices were improved to a degree after felodipine therapy. However, it must be noted that this improvement was small, while in patients who did not satisfactorily reduce their DBP levels (90-94 mm Hg under treatment) it was non-existent.
The vasodilation caused by felodipine, improves cardiac output in parallel to the fall of peripheral resistances. In acute administration, where the reflex tachycardia is profound, the total peripheral resistances are reduced up to 40%. In chronic use, a reduction in total peripheral resistances by 15% after 1 year of treatment with felodipine in 16 hypertensive men is reported. 35 In the present study, total peripheral resistance was reduced by 14% in all patients, relatively more so (−17%) in patients with the greater BP fall. Cardiac output was improved by only 2.4% without differentiation according to BP levels under treatment.
The wall hypertrophy of the resistance vessels is the result of chronic hypertension as much as the basic mechanism to sustain the increased BP. However, the large arteries are also subject to time wear and to the increased pressure load with progressive wall thickening and loss of their elastic properties. 36 Aortic root distensibility improvement is today one of the targets of anti-hypertensive therapy and can be achieved with a variety of drugs. Calcium antagonists have been shown to improve the vascular structure and function in canines as well as in humans. Felodipine improves large artery function, not only haemodynamically by pressure load reduction, but also through direct action on the smooth vascular muscle cells. In the present study the distensibility of aorta was improved by 56% after a 6-month therapy with felodipine in a total of 600 patients. This improvement was proportional to the degree of BP fall, as expected, with the progressive decrease of shear force wave on the aortic wall. But, the diastolic expansion of the aortic root was also increased in parallel to the BP fall, indicating the immediate action of this drug on the vascular wall, 37 in addition to the improvement of the haemodynamic conditions. 38 As shown in the present study, the degree of improvement of the structural and functional characteristics of the cardiovascular system after anti-hypertensive therapy with felodipine depends on many parameters, like the age and the demographic patient characteristics, and the BP levels achieved through treatment. The latter can be used as a strong indication of the individual answer of a patient for the prediction of the expected therapy benefits.
